Download Experience a new type of immunity!

®
with
®
The NEW COMBINED VACCINE against neonatal
diarrhoea in piglets and sudden death in sows
Experience a new type of immunity!
®
The guidelines on the development of new adjuvants play a d
between the non-specific immune respon
HIPRAMUNE®-G is the new a
based on saponins e
extracted f
Non-specific
Immune
response
Ginsenosidess
Attract and stimulate
the production and maturation
of mononuclear cells, dendritic
cells and macrophages 8,9.
Light
Ginsenosides induce the
Ginsenosides
capturee of the antigen
Rough
endoplasmic
reticulum
Antigen/ginsenoside
The antigen, dendritic cells and
macrophages, presenting cells are
responsible for capturing the antigen
and presenting it to the rest of the
immunological system.
Nucleus
Transporter
MHC class I
Golgi complex
MHC class I
molecule
Immunohistocompatibility I complex
Cytotoxic cells/NK
Dendritic cell
®
is the first vaccine marketed that includes this
Light and potent
determining role in the mediation and establishment of a link
nse and the adaptive immune response6.
adjuvant developed by HIPRA
rom GINSENG: GIN
GINSENOSIDES
Immunological studies conducted at the HIPRA R&D Department have demonstrated that HIPRAMUNE®-G:
Lynphatic vessel
■ Stimulates production of peripheral mononuclear cells (this cell
population is key at the inoculation site of a vaccine for giving a
proper immunological response).
Lymphatic
ganglia
The combination of a water-based adj
adjuvant
(aluminium hydroxide) and ginsenosid
ginsenosides
modulates the cellular and humoral
response, thereby inducing improved
protection9.
T-helper cell
■ Stimulates the maturation of dendritic
cells, thereby improving an animal’s
antigen presentation process.
Potent
MHC class II
Immunohistocompatibility II
complex
Adaptative
Immune
Response
MHC class II
molecule
Lymphocyte B/Plasmatic cell
T-helper cell
A water-based adjuvant
with ginsenosides increases
production of antibodies in
comparison with conventional
water-based adjuvants10.
Cytotoxic T cellsNK
innovative technology:
®
with
®
Efficaciously induces
antibody production
L
IGHT
Greater vaccinal safety
Thanks to its new g
generation water-based adjuvant,
:
®
Forget
about lumps
on the neck!
Does not produce FEVER
Does not have ADVERSE REACTIONS
Does not cause LUMPS at the inoculation site
The safest vaccine
An experimental study conducted with SUISENG® and the leading vaccines marketed for preventing neonatal diarrheoa assessed their SAFETY. The results
demonstrated that SUISENG® was the safest vaccine in the test.
Progress of rectal temperatures in each treatment group
VACCINATION
REVACCINA
REVACCINATION
41,00
40,50
40,00
39,50
39,00
Day 1
Day 0
Day 0
+2h
Day 0
+4h
Day 0
+6h
Day 1
Day 2
Day 3
Day 20
Vaccination
Day 21
Day 21
+2h
Day 21
+4h
Day 21
+6h
Day 22
Day 23
Day 24
Revaccination
■ SUISENG®
■ Vaccine 1 (5 ml/dose with AI (OH)3
■ Vaccine 2 (2 ml/dose with α-Tocoferol)
■ Placebo
Percentage of animals that showed some general or local sign after administration of the treatments
VACCINATION
REVACCINATION
62,5
General signs:
fever, depression
and listlessness.
*
75,0
*
62,5
50,0
*
37,5
25,0
Local signs:
inflammatory
reaction at
inoculation site.
0
0
% General signs
0
12,5
0
% Local signs
0
0
% General signs
0
12,5
% Local signs
*
There are significant differences compared to the SUISENG® group.
Optimal vaccinal safety with a light and potent adjuvant:
®
12,5
POTENT
Better protection
improved protection against neonatal
diarrheoa under experimental conditions*
*
In comparison with another water-based combined vaccine against E. coli and Cl. perfringens
The potency of SUISENG® is demonstrated in a challenge trial with E. coli1
Three groups of 1-day-old piglets were chosen that had
properly ingested colostrum and they were challenged
with a strain of enteropathogenic E. coli.
Non-vaccinated
control
Commercial vaccine
(5 ml/dose)
SUISENG®
(2 ml/dose)
65,0
65,0
% of diarrhoea and mortality
in the first week of life
37,5
35,3
32,4
14,7
3,4
% Mortality
13,8
10,3
% Diarrhoea
a
Morbidity
(% Diarrhoea and/or
Mortality)
HYPERIMMUNIZATION of the colostrum demonstrated!
Well immunised colostrum in the first week of life is fundamental
for preventing the incidence of diarrhoea in the farrowing pen
HIPRA’s R&D services conducted a study2 in NULLIPAROUS animals to assess quantitatively and qualitatively
the production of specific antibodies against the main adhesion factors of the strains of E. coli and the β toxin
of Cl. perfringens in the colostrum of sows.
Hyperimmunization against E. coli
The findings demonstrate SUISENG®’s capacity for hyperimmunisation of colostrum against neonatal colibacillosis.
Antibody titres in piglets
12 hours post-partum
SUISENG®
Placebo
LT
65,8
31,3
F4 ab
114,9
38,7
F4 ac
93,5
17,3
F6
68,3
4,4
F5
30,3
10,9
Hyperimmunzation against necrotic enteritis
in piglets (Cl. perfringens type C)
Titres of neutralising antibodies of the type C Cl. perfringens β toxin higher than
5IU/ml of colostrum significantly prevent the mortality caused by necrotic enteritis
in litters of piglets3.
CONTROL
Titres >5 UI/ml
Titres: 0 UI/ml
The most complete vaccine:
TRIPLE protection
is the only vaccine that prevents
neonatal diarrheoa in piglets caused by E. coli and
Cl. perfringens type C and neutralises the α toxin of
Clostridium novyi responsible for sudden death in sows
sudden death of lactating sows caused by Clostridium novyi
Clostridium novyi types A and B is a Gram-positive anaerobic bacterium. Acute infection caused
by it is considered the most significant cause of mortality in breeder sows11,12,13.
SUDDEN DEATH of sows is a problem that mainly affects sows in the last trimester of gestation
and LACTATING BREEDERS12,13.
α
α
α
α
α
α
α
α
α
α
Cl. Novyi ’s pathogenesis is
mediated by the lethal
necrotising α TOXIN.
α toxin
Systemic dissemination of the α TOXIN
produces cardio, neuro, histo and hepatotoxic
effects that result in ACUTE or HYPERACUTE
DEATH11.
Reduction
of the farm
productivity
Elevated mortality
Increase of
the replacement
rate
TRIPLE protection:
■
Neonatal diarrhoea caused
by E. coli
■
Necrotic enteritis of piglets
caused by Cl. perfringens
■
Neutralization of the
Cl. Novyi α toxin
Efficaciously induces serum
neutralising antibodies against
the α toxin
HIPRA’s R&D Department assessed the capacity to induce SERUM
NEUTRALISING ANTIBODIES against the α TOXIN of Clostridium novyi
in breeder sows vaccinated with SUISENG®.
CONTROL
Physiologic
Solution
α
α
α
1
2
3
α Toxin
1
2
3
They collected serum from sows vaccinated
with SUISENG®, and sows inoculated with
physiological serum were maintained as a
CONTROL group at the time of farrowing
(3 weeks after the 2nd vaccination).
These sera were mixed with the purified α
TOXIN of Cl. novyi.
α
α
α
They were inoculated in mice to assess
the mortality induced by the toxin.
The findings demonstrated the capacity
of the sera of the sows vaccinated
with SUISENG® to neutralise
TOXIN.
α
4
100% alive
100% dead
SUISENG PROTECTS B
REEDER SOWS
®
AND THEIR
RP
PIGLETS
IGLETS
®
®
with
A MORE COMPLETE, EFFICACIOUS AND SAFE VACCINE
■
■
■
■
■
■
Light and potent
Better protection against neonatal diarrhoea caused
by E. coli and Clostridium perfringens type C
Greater antigenic spectrum
Neutralizes the Clostridium novyi α toxin responsible
for SUDDEN DEATH in lactating sows
Protection of breeder sows and their piglets
Maximum safety
1. Estudio PE-05-CB-25.
2. Estudio PE-06-09.
3. Ripley PH, Gush AF. “Immunisation Schedule for the prevention of infectious necrotic enteritis caused by Clostridium perfringens type C in piglets”. Vet REc.
1983 Feb 26;112 (9): 201-2.
4. Estudio PE-06-CB-18.
5. Estudio PE-05-CB-31.
6. Garlapati, S., M. Facci, M. Polewicz, S. Strom, L.A. Babiuk, G. Mutwiri, R.E. Hancock, M.R. Elliott, and V. Gerdts. Strategies to link innate and adaptive
immunity when designing vaccine adjuvants. Vet. Immunol. Immunopathol. 2008.
7. Masao Takei, Eiichi Tachikawa, Hideo Hasegawa, Je-Jung Lee. “Dendritic cells maduration promoted by M1 and M4 end products of steroideal ginseng saponings
metabolized in digestive tracts, drive a potent TH1 polaritation”. Bioch. Pharmacology 68 (2004). 441-452.
8. Rajput, Z.I., S.H. Hu, C.W. Xiao, and A.G. Arijo. Adjuvant effects of saponins on animal immune responses. J. Zhejiang. Univ Sci. B. 8:153-161. 2007.
9. Sun, Y., H. Tong, M. Li, Y. Li, S. Guan, and J. Liu. Immunological adjuvant effect of Japanese ginseng saponins (JGS) on specific antibody and cellular response to
ovalbumin and its haemolytic activities. Vaccine. 2008.
10. Rivera, E., A. Daggfeldt, and S. Hu. Ginseng extract in aluminium hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and
Erysipelothrix rhusiopathiae. Vet. Immunol. Immunopathol. 91:19-27. 2003.
11. Itoh, H; Uchida, M.; Sugiura, H.; Ogusu, S.; Yamakawa, K. “Outbreak of Clostridium novyi infection in swine and its rapid diagnosis Journal of the Japanese Veterinary
Medical Association (1983) 40:365-369.
12. Duran, CO.; Walton, JR. “Clostridium novyi sudden death in sows: toxemia o post mortem invader? Pig Journal 39:7-53 (1987).
13. Shultz, RAet al. (2001) A sow mortality study-the real reasons sows die: identigying causes and implementing action. Proc Am Assoc Swine Vet. 387-395.
SUISENG®: COMPOSITION PER DOSE (2 ml): F4ab fimbrial adhesin of E. coli ≥ 65% ER60*; F4ac fimbrial adhesin of E. coli ≥78% ER70; F5 fimbrial adhesin of E. coli ≥ 79%
ER50; F6 fimbrial adhesin of E. coli ≥ 80% ER25; LT Enterotoxoid of E. coli ≥ 55% ER70; Toxoid Clostridium perfringens, type C ≥ 35% ER25. Toxoid Clostridium novyi ≥ 50%
ER120 *% ERx: Percentage of immunized rabbits with a X serological EIA response. Adjuvant based on Aluminium hydroxide and Ginseng extract. INDICATIONS: Swine: For the
passive protection of neonatal piglets by means of the active immunisation of breeding sows and gilts to reduce mortality and clinical signs of neonatal enterotoxicosis and
Necrotic Enteritis. For active immunisation of breeding sows and gilts to induce seroneutralizing antibodies against α-toxin of Clostridium novyi.
Laboratorios Hipra, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
Spain
ADMINISTRATION ROUTE: Intramuscular, into the neck muscles.
Basic vaccination
Revaccination
1st dose
2nd dose
6 weeks
3 weeks
1st dose
FARROWING
6 weeks
3 weeks
FARROWING
Swine: 2 ml/animal. The basic vaccination scheme consists of two doses: the first dose at approximately 6 weeks before farrowing and a second dose at approximately
3 weeks before farrowing. Revaccination: on each subsequent gestation, administer one dose 3 weeks before the expected date of farrowing. WITHDRAWAL PERIOD:
0 days. SPECIAL PRECAUTIONS: Store and transport refrigerated (2 ºC and 8 ºC). Protect from light. Do not freeze. PACKAGING: 1 vial of 10 ds, 1 vial of 25 ds, 1 vial of
50 ds. Under veterinary prescription. FOR VETERINARY USE ONLY. Reg. Nº: 2085 ESP.
Tel. (34) 972 43 06 60
Fax (34) 972 43 06 61
[email protected]
www.hipra.com